首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1771289

补体抑制剂市场:产业趋势和全球预测 - 各适应疾病，各治疗领域，各分子类型，各标的途径，治疗类别，各给药途径，主要各地区

Complement Inhibitors Market: Industry Trends and Global Forecasts - Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Key Geographical Regions

出版日期: 2025年07月15日 | 出版商:

Roots Analysis | 英文 131 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计2035年，全球补体抑制剂市场规模将从目前的91亿美元成长至78亿美元，预测期内复合年增长率为15%。

市场区隔包括以下参数的市场规模与机会分析：

适应疾病

非典型溶血性尿毒症症候群
心臟移植排斥反应
冷血球凝集素病
COVID-19
全身性重症肌无力
格林-巴利症候群
遗传性血管水肿
视神经脊髓炎
阵发性夜间血尿症

治疗领域

心血管疾病
遗传性疾病
血液·血管疾病
感染疾病
神经疾病
神经肌肉疾病

分子类型

生物製药
低分子

标的途径

替代途径
古典的途径
凝集素途径
末端途径

治疗类型

单剂疗法
联合治疗

给药途径

静脉注射
口服
皮下

主要地区

北美
欧洲
亚太地区

全球补体抑制剂市场:成长和趋势

补体系统于19世纪被发现，是免疫系统的一部分，参与组织修復和体内平衡，从而提供抵御多种感染的第一道防线。整个过程与复杂且高度受调控的蛋白质组装有关，涉及多种可溶性和表面结合补体成分，包括受体和调节剂，主要在肝臟中产生。这些蛋白质构成了补体疗法的基础，与多种免疫细胞相互作用，并补充抗体的作用。此外，补体系统透过促进凋亡细胞的清除和控制细胞存活，有助于维持健康生物体的体内平衡。然而，补体活化不足会导致病原体增殖、补体调节因子被抑制，最终导致疾病。因此，人们开发了抑制补体系统活化的疗法，以帮助减少组织发炎并调节对外来和自体抗原的适应性免疫反应。

在鼓励临床研究、新製药公司进入、疾病重点扩大以及以创新方式超越C5药物的愿望日益增强的推动下，补体抑制剂市场预计将在未来十年获得製药市场的显着占有率，届时将有更多候选药物获批上市。

全球补体抑制剂市场：关键洞察

本报告深入探讨了全球补体抑制剂市场的现状，并识别了该行业内的潜在成长机会。报告的主要发现包括：

全球各大製药公司正在研究超过190种针对补体系统治疗多种疾病的候选药物。
目前，大多数（约80%）补体疗法正在临床试验中进行评估，其中超过75%的候选药物为生物製剂，尤其是单株抗体。
北美已成为该市场的中心，约有50%的研发商聚集于此。目前，该市场由中型公司主导（占利害关係人总数的37%）。值得注意的是，15%的参与者是大型製药公司，他们参与了多个治疗领域的此类疗法的开发。

迄今为止，已有超过850项与补体疗法相关的临床试验註册，其中大多数（53%）在欧洲的各个临床研究中心进行。
据报道，就註册试验数量而言，临床研究活动在此期间以21%的复合年增长率增长。在註册试验总数中，近60%已经完成，而24%的试验仍在招募参与者。
多篇以补体疗法为主题的论文已发表在具有较高作者影响力的知名期刊上。
近年来，与补体疗法相关的论文数量逐渐增加，共发表了1,460篇研究论文。
超过40%的关于下一代补体疗法的论文发表于2019年之后。
"免疫学前沿" 是最受欢迎的期刊，其中大部分论文关注传染病（21%）和肾臟病（16%）。
已向各组织拨款超过8亿美元，以支持正在进行的新型补体疗法创新研究。其中约20%的拨款由美国国家癌症研究所资助。
与补体疗法相关的专利申请数量的不断增长表明利益相关者对该领域的关注度日益增长，以及该领域广泛的研发工作。
该领域已提交/授予超过3,490项与补体疗法相关的专利。这一数字归功于该领域持续不断的研发工作。
超过60%的补体疗法相关专利申请是由各行各业的参与者提交的，例如AbbVie和Alexion Pharmaceuticals。
这主要是由于近期提交的专利被引用次数较低。
高达45%的合作协议是为了产品开发和商业化而签署的。此外，大多数协议是由北美参与者签署的（66%）。
意识到该领域的机遇，多家投资者已在74轮融资中投资了总计约142亿美元。
约40%的该领域公司主要透过二次发行筹集资金。此外，70%的融资案例来自总部位于北美的公司。
大型製药公司正在采取一系列举措，从专有产品开发到策略性投资。
凭藉着前景广阔的开发管道和令人鼓舞的临床研究成果，补充疗法市场预计未来十年将以每年超过 15% 的速度成长。

在各种标靶途径、治疗类型、给药途径和主要地理区域，补充疗法市场机会呈现多元化。

补体抑制剂市场参与企业案例

Amgen
CSL Behring
Innovent Biologics
Novartis
Regeneron
Roche
Sanofi
Takeda
UCB

初步研究概述

本研究中表达的观点和见解受到与多位利害关係人讨论的影响。研究报告包含对以下产业参与者的详细访谈：

医生，公司A
血液科/肿瘤科，公司B
高级科学顾问，公司C
肾臟科临床医师/科学家，公司D
肾臟科教授，公司E

本报告概述了全球补体抑制剂市场，包括按适应症、治疗领域、分子类型、标靶途径、治疗类型、给药途径、区域趋势和公司概况划分的市场趋势。

补体系概要
补体系干预的免疫细胞
补体系的特征
补体系的功能
恆常性和压力状态的补体所扮演的角色
补体系的活性化
主要的补体蛋白质的供给来源
古典的途径的补体蛋白质的功能
补体系的途径
补体系的调节不全影响
补体蛋白质的缺陷相关的疾病
补体疗法的种类
补体疗法的限制
下一代补体治疗药的未来

第4章下一代补体治疗药:市场形势

分析调查手法和主要参数
下一代补体治疗药:开发平台
下一代补体治疗药:特别指定药物一览
下一代补体治疗药:开发形势

第5章企业简介

Amgen
CSL Behring
Innovent Biologics
Novartis
Regeneron
Roche
Sanofi
Takeda
UCB

第6章临床试验的分析

分析调查手法和主要参数
下一代补体治疗药:临床试验一览

第7章出版物的分析

分析调查手法和主要参数
下一代补体治疗药:出版物一览

第8章津贴分析

分析调查手法和主要参数

第9章专利分析

分析调查手法和主要参数
下一代补体治疗药:专利一览

第10章伙伴关係和合作

下一代补体治疗药:联盟·合作清单

第11章与资金筹措投资分析

下一代补体治疗药:资金筹措和投资的清单

第12章大型製药公司

分析调查手法和主要参数
参数的评分
大型製药公司:收益相关资讯

第13章市场规模的评估与机会分析

预测调查手法和主要参数
到2035年前的全球下一代补体治疗药市场
到2035年前的成药作为对象的全球下一代补体治疗药市场
市售医药品的各产品预测销售额
- Berinert (CSL Behring)
- EMPAVEL
- ORLADEYO（BioCryst 製药公司）
- Ruconest（医药）
- Soliris（Alexion 药厂）
- 卓次郎（武田）
- Ultomiris（Alexion 药厂）
到2035年前的第三阶段医药品的下一代补体治疗药的全球市场
第三阶段医药品的各产品预测销售额
- Narsoplimab（Omeros）
- REGN3918（再生元）
- RG6107（Ruconest）
- rVA576（Akari Therapeutics）
- SAR445088（赛诺菲）
- Soliris（Alexion 药厂）
- Stimulimab（Bioverativ）
- 比洛贝利单抗 (InflaRx)
- 齐尔科普兰(UCB)
摘要:第三阶段的药物

第14章专家的意见

第15章附录1:图表一览

第16章附录2:企业·团体一览

简介目录图表

Product Code: RA100355

GLOBAL COMPLEMENT INHIBITORS MARKET: OVERVIEW

As per Roots Analysis, the global complement inhibitors market is estimated to grow from USD 9.1 billion in the current year to USD 7.8 billion by 2035, at a CAGR of 15% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Target Disease Indication

Atypical Hemolytic Uremic Syndrome
Cardiac Transplantation Rejection
Cold Agglutinin Disease
COVID-19
Generalized Myasthenia Gravis
Guillain-Barre Syndrome
Hereditary Angioedema
Neuromyelitis Optica
Paroxysmal Nocturnal Hemoglobinuria

Therapeutic Area

Cardiovascular Disorders
Genetic Disorders
Hematological and Vascular Disorders
Infectious Diseases
Neurological Disorders
Neuromuscular Disorders

Type of Molecule

Biologic
Small Molecule

Target Pathway

Alternate Pathway
Classical Pathway
Lectin Pathway
Terminal Pathway

Type of Therapy

Monotherapy
Combination Therapy

Route of Administration

Intravenous
Oral
Subcutaneous

Key Geographical Regions

North America
Europe
Asia-Pacific

GLOBAL COMPLEMENT INHIBITORS MARKET: GROWTH AND TRENDS

Complement system was discovered in the 19th century as a part of immune system, responsible for tissue repair and homeostasis, thereby providing first line of defense against multiple infections. This complete process is in association with a complex and highly regulated assembly of proteins which involve several soluble and surface-bound complement components, including receptors and regulators, which are primarily generated by the liver. These proteins, making the base for complement therapeutics, interact with multiple immune cells and complement the action of antibodies, which are in turn responsible for killing the infectious agents. Additionally, the complement system contributes to maintaining homeostasis in healthy organisms by facilitating the clearance of apoptotic cells and regulating cell survival. However, when complement activation is insufficient, pathogens can proliferate, and the suppression of complement regulators may occur, ultimately leading to disease. Consequently, therapeutics targeting the complement system have been developed to inhibit its activation, which helps reduce tissue inflammation and modulate the adaptive immune response to both foreign and self-antigens.

Driven by encouraging clinical research efforts, new pharmaceutical entrants, broadening of disease focus, and a rising desire to get beyond C5 with some innovative ways, the complement inhibitors market is expected to capture a significant share in the pharmaceutical market with more drug candidates getting approved and marketed over the coming decade.

GLOBAL COMPLEMENT INHIBITORS MARKET: KEY INSIGHTS

The report delves into the current state of global complement inhibitors market and identifies potential growth opportunities within industry. Some key findings from the report include:

Over 190 therapeutic candidates, targeting complement system for the treatment of multiple disease indications, are being investigated by various pharmaceutical companies across the globe.
Majority (~80%) of complement therapeutics are currently being evaluated in clinical trials; more than 75% of the pipeline candidates are biologics, specifically monoclonal antibodies.
North America has emerged as the hub, featuring the presence of approximately 50% developers. The market is currently dominated by the presence of mid-sized players (37% of the total number of stakeholders). Interestingly, 15% of the players are big pharma companies engaged in the development of such therapeutics for multiple therapeutic areas.

850+ clinical trials related to complement therapeutics have been registered till date; majority (53%) of these trials were / are being conducted across various clinical sites based in Europe.
The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 21%, during the given period. Of the total number of trials registered, close to 60% have already been completed, while 24% of the studies are actively recruiting participants.
A variety of articles focused on complement therapeutics have been published by eminent authors in high-impact journals.
Over the years, there has been a gradual rise in the number of publications related to complement therapeutics; 1,460 research articles were published during the given time period.
More than 40% of the articles focused on next generation complement therapeutics were published post-2019.
Frontiers in Immunology emerged to be the most popular journal with majority of the publications focused on infectious diseases (21%) and renal disorders (16%).
Grants worth over USD 800 million have been awarded to various organizations in order to support the ongoing research efforts for innovation of novel complement therapeutics. Around 20% of the grants were funded by the National Cancer Institute.
The increasing number of patents being filed for complement therapeutics is indicative of the rising interest of stakeholders and extensive R&D efforts being undertaken in this field.
Over 3,490 patents related to complement therapeutics have been filed / granted in this domain; this number can be attributed to the incessant R&D efforts being made in this domain.
More than 60% of the patent applications have been filed for complement therapeutics by various industry players; examples include AbbVie and Alexion Pharmaceuticals.
Only 4% of the patents have a significantly higher relative valuation; this is primarily because of the low number of citations of the patents filed recently.
Maximum, over 45% of the partnerships were signed for product development and commercialization purposes. Further, majority of the agreements were signed by players based in North America (66%).
Several investors, having realized the opportunity within this segment, have collectively invested a sum of ~USD 14.2 billion, across 74 funding instances.
Around 40% of the companies engaged in this domain primarily received funding through secondary offerings. Further, 70% of the funding instances were reported by players headquartered in North America.
Big pharma players have undertaken a variety of initiatives, ranging from proprietary product development to strategic investments.
With a promising development pipeline and encouraging clinical research outcomes, the complement therapeutics market is anticipated to grow at an annualized rate of more than 15%, over the next decade.

The opportunity is likely to be well distributed across various target pathways, types of therapies, routes of administration and key geographical regions.

Example Players in the Complement Inhibitors Market

Amgen
CSL Behring
Innovent Biologics
Novartis
Regeneron
Roche
Sanofi
Takeda
UCB

PRIMARY RESEARCH OVERVIEW

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews conducted with the following industry stakeholders:

Physician, Company A
Hematologist Oncologist, Company B
Senior Scientific Consultant, Company C
Nephrology Clinician-Scientist, Company D
Professor of Nephrology, Company E

GLOBAL COMPLEMENT INHIBITORS MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global complement inhibitors market, focusing on key market segments, including [A] target disease indication, [B] therapeutic area, [C] type of molecule, [D] target pathway, [E] type of therapy, [F] route of administration and [G] key geographical regions.
Market Landscape: A comprehensive evaluation of next generation complement therapeutics, considering various parameters, such as [A] status of development, [B] type of molecule, [C] type of drug, [D] biological target, [E] target pathway, [F] mechanism of action, [G] target disease indication(s), [H] therapeutic area(s), [I] route of administration, [J] type of therapy and [K] dosing frequency. Additionally, the section includes a comprehensive evaluation of players developing next generation complement therapeutics based on parameters, such as [A] year of establishment, [B] company size and [D] location of headquarters.
Company Profiles: In-depth profiles of companies engaged in the development of next generation complement therapeutics, focusing on [A] company overview, [B] financial information (if available), [C] product portfolio and [D] recent developments and an informed future outlook.
Clinical Trial Analysis: A comprehensive analysis of clinical studies of various next generation complement therapeutics, examining factors, such as [A] current trial status, [B] trial registration year, [C] trial phase, [D] enrolled patient population, [E] type of sponsor / collaborator, [F] type of study, [G] study design, [H] leading industry and non-industry players, [I] key indication(s), [J] popular therapeutics area(s), [K] type of treatment, [L] type of drug, [M] emerging focus areas and [N] regional distribution of trials.
Publication Analysis: An insightful analysis of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, based on various relevant parameters, such as [A] year of publication, [B] emerging focus areas, [C] top authors, [D] key research journals, [E] popular indication(s) and [F] therapeutic area(s).
Grant Analysis: A detailed analysis of grants awarded to various research institutes for the projects related to next generation complement therapeutics, based on various relevant parameters, such as [A] year of grant awarded, [B] amount awarded, [C] funding institute center, [D] support period, [E] type of grant, [F] activity code while highlighting popular recipient organizations, [F] popular NIH departments, [G] study section, [H] type of recipient organization, [I] emerging focus areas of the grants, [J] purpose of grant awarded, [K] prominent program officers and [L] location of recipient organizations.
Patent Analysis: An insightful analysis of patents filed / granted for next generation complement therapeutics, based on various relevant parameters, such as [A] patent publication year, [B] type of patent, [C] geographical location, [D] CPC symbols, [E] type of applicant, [F] patent age, [G] emerging focus areas, [H] leading industry and non-industry players (in terms of number of patents granted / filed), [I] patent characteristics, [J] patent benchmarking and [K] patent valuation.
Partnerships and Collaborations: A comprehensive analysis of deals inked by stakeholders in this domain, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] biological target, [D] target pathway, [E] emerging focus area, [F] type of partner, [G] popular disease indication, [H] therapeutic area and [I] geographical distribution of partnership activity.
Funding and Investments: An in-depth analysis of the fundings raised by companies engaged in complement inhibitors market, based on relevant parameters, such as [A] year of funding, [B] amount invested, [C] type of funding, [D] geographical analysis, [E] most active players and [F] most active investors.
Big Pharma Players: A comprehensive analysis of big pharma players engaged in the field of complement inhibitors market, based on several relevant parameters, such as [A] number of therapeutics under development, [B] type of molecule, [C] status of development, [D] number of therapeutic areas, [E] number of partnerships, [F] number of patents and [G] years of experience.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
- 1.2.1. Research Assumptions
- 1.2.2. Project Methodology
- 1.2.3. Forecast Methodology
- 1.2.4. Robust Quality Control
- 1.2.5. Key Considerations
  - 1.2.5.1. Demographics
  - 1.2.5.2. Economic Factors
  - 1.2.5.3. Government Regulations
  - 1.2.5.4. Supply Chain
  - 1.2.5.5. COVID Impact / Related Factors
  - 1.2.5.6. Market Access
  - 1.2.5.7. Healthcare Policies
  - 1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Overview of Complement System
3.2. Immune Cells Involved in Complement System
3.3. Characteristics of Complement System
3.4. Functions of Complement System
3.5. Role of Complement in Homeostasis and Stress Conditions
3.6. Activation of Complement System
- 3.6.1. Steps in Complement Activation
3.7. Sources of Key Complement Proteins
3.8. Functions of Complement Proteins of Classical Pathway
3.9. Pathways of Complement System
- 3.9.1. Classical Pathway
- 3.9.2. Lectin Pathway
- 3.9.3. Alternative Pathway
- 3.9.4. Terminal Pathway
3.10. Consequences of a Dysregulated Complement System
3.11. Diseases related to Defects in Complement Proteins
3.12. Types of Complement Therapeutics
3.13. Limitations of Complement Therapeutics
3.14. Future of Next Generation Complement Therapeutics

4. NEXT GENERATION COMPLEMENT THERAPEUTICS: MARKET LANDSCAPE

4.1. Analysis Methodology and Key Parameters
4.2. Next Generation Complement Therapeutics: Development Pipeline
- 4.2.1. Analysis by Status of Development
- 4.2.2. Analysis by Type of Molecule
- 4.2.3. Analysis by Status of Development and Type of Molecule
- 4.2.4. Analysis by Type of Drug
- 4.2.5. Analysis by Biological Target
- 4.2.6. Analysis by Target Pathway
- 4.2.7. Analysis by Mechanism of Action
- 4.2.8. Analysis by Mechanism of Action and Target Pathway
- 4.2.9. Analysis by Target Disease Indication(s)
- 4.2.10. Analysis by Status of Development and Target Disease Indication(s)
- 4.2.11. Analysis by Therapeutic Area
- 4.2.12. Analysis by Therapeutic Area and Type of Molecule
- 4.2.13. Analysis by Route of Administration
- 4.2.14. Analysis by Type of Therapy
- 4.2.15. Analysis by Dosing Frequency
- 4.2.16. Grid Analysis: Type of Therapy, Type of Molecule, Route of Administration and Mechanism of Action
4.3. Next Generation Complement Therapeutics: List of Drugs with Special Designations
- 4.3.1. Analysis by Special Designation
4.4. Next Generation Complement Therapeutics: Developer Landscape
- 4.4.1. Analysis by Year of Establishment
- 4.4.2. Analysis by Company Size
- 4.4.3. Analysis by Region of Headquarters
- 4.4.4. Analysis by Company Size and Region of Headquarters
- 4.4.5. Leading Players: Analysis by Number of Therapeutics

5. COMPANY PROFILES

5.1. Amgen
- 5.1.1. Company Overview
- 5.1.2. Financial Information
- 5.1.3. Product Portfolio
- 5.1.4. Recent Developments and Future Outlook
5.2. CSL Behring
- 5.2.1. Company Overview
- 5.2.2. Financial Information
- 5.2.3. Product Portfolio
- 5.2.4. Recent Developments and Future Outlook
5.3. Innovent Biologics
- 5.3.1. Company Overview
- 5.3.2. Financial Information
- 5.3.3. Product Portfolio
- 5.3.4. Recent Developments and Future Outlook
5.4. Novartis
- 5.4.1. Company Overview
- 5.4.2. Financial Information
- 5.4.3. Product Portfolio
- 5.4.4. Recent Developments and Future Outlook
5.5. Regeneron
- 5.5.1. Company Overview
- 5.5.2. Financial Information
- 5.5.3. Product Portfolio
- 5.5.4. Recent Developments and Future Outlook
5.6. Roche
- 5.6.1. Company Overview
- 5.6.2. Financial Information
- 5.6.3. Product Portfolio
- 5.6.4. Recent Developments and Future Outlook
5.7. Sanofi
- 5.7.1. Company Overview
- 5.7.2. Financial Information
- 5.7.3. Product Portfolio
- 5.7.4. Recent Developments and Future Outlook
5.8. Takeda
- 5.8.1. Company Overview
- 5.8.2. Financial Information
- 5.8.3. Product Portfolio
- 5.8.4. Recent Developments and Future Outlook
5.9. UCB
- 5.9.1. Company Overview
- 5.9.2. Financial Information
- 5.9.3. Product Portfolio
- 5.9.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

6.1. Analysis Methodology and Key Parameters
6.2. Next Generation Complement Therapeutics: List of Clinical Trials
- 6.2.1. Analysis by Trial Status
- 6.2.2. Cumulative Analysis by Trial Registration Year
- 6.2.3. Analysis by Trial Registration Year and Status
- 6.2.4. Analysis by Trial Phase
- 6.2.5. Analysis by Trial Phase and Patients Enrolled
- 6.2.6. Analysis by Trial Registration Year and Patients Enrolled
- 6.2.7. Analysis by Type of Sponsor / Collaborator
- 6.2.8. Analysis by Type of Study
- 6.2.9. Analysis by Study Design
- 6.2.10. Most Active Industry Players: Analysis by Number of Trials
- 6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
- 6.2.12. Analysis by Disease Indication
- 6.2.13. Most Popular Therapeutic Areas: Analysis by Number of Trials
- 6.2.14. Analysis by Type of Treatment
- 6.2.15. Analysis by Type of Drug
- 6.2.16. Word Cloud Analysis: Emerging Focus Areas
- 6.2.17. Analysis by Top Indications and Phase of the Trial
- 6.2.18. Analysis by Top Indications and Leading Industry Players
- 6.2.19. Analysis by Trial Location
- 6.2.20. Analysis by Geography and Trial Status

7. PUBLICATION ANALYSIS

7.1. Analysis Methodology and Key Parameters
7.2. Next Generation Complement Therapeutics: List of Publications
- 7.2.1. Analysis by Year of Publication
- 7.2.2. Word Cloud Analysis: Emerging Focus Areas
- 7.2.3. Top Authors: Analysis by Number of Publications
- 7.2.4. Key Journals based on Number of Publications
- 7.2.5. Key Journals based on Impact Factor
- 7.2.6. Popular Indications based on Number of Publications
- 7.2.7. Popular Therapeutic Areas based on Number of Publications

8. GRANT ANALYSIS

8.1. Analysis Methodology and Key Parameters
- 8.1.1. Analysis by Year of Grants Awarded
- 8.1.2. Analysis by Amount Awarded
- 8.1.3. Analysis by Funding Institute Center
- 8.1.4. Analysis by Support Period
- 8.1.5. Analysis by Funding Institute Center and Support Period
- 8.1.6. Analysis by Type of Grant
- 8.1.7. Analysis by Activity Code
- 8.1.8. Popular Recipient Organizations: Analysis by Number of Grants
- 8.1.9. Popular Recipient Organizations: Analysis by Amount Awarded
- 8.1.10. Popular NIH Departments: Analysis by Number of Grants
- 8.1.11. Analysis by Study Section
- 8.1.12. Analysis by Type of Recipient Organization
- 8.1.13. Word Cloud Analysis: Emerging Focus Areas
- 8.1.14. Analysis by Purpose of Grant
- 8.1.15. Prominent Program Officers: Analysis by Number of Grants
- 8.1.16. Analysis by Location of Recipient Organizations

9. PATENT ANALYSIS

9.1. Analysis Methodology and Key Parameters
9.2. Next Generation Complement Therapeutics: List of Patents
- 9.2.1. Analysis by Patent Publication Year
- 9.2.2. Analysis of Year-wise Granted Patents
- 9.2.3. Analysis by Type of Patent
- 9.2.4. Analysis by Granted Patents and Patent Applications
- 9.2.5. Analysis by Geography
- 9.2.6. Analysis by CPC Symbols
- 9.2.7. Analysis by Type of Applicant
- 9.2.8. Analysis of Patents by Age
- 9.2.9. Word Cloud Analysis: Emerging Focus Areas
- 9.2.10. Leading Industry Players: Analysis by Number of Patents
- 9.2.11. Leading Non-Industry Players: Analysis by Number of Patents
- 9.2.12. Leading Individual Assignees: Analysis by Number of Patents
- 9.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
- 9.2.14. Patent Valuation: Analysis Methodology and Parameters
- 9.2.15. Patent Valuation: Analysis by Relative Valuation

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Next Generation Complement Therapeutics: List of Partnerships and Collaborations
- 10.1.1. Analysis by Year-wise Trend of Partnership
- 10.1.2. Analysis by Type of Partnership
- 10.1.3. Analysis by Year and Type of Partnership
- 10.1.4. Most Popular Drug: Analysis by Number of Partnerships
- 10.1.5. Analysis by Biological Target
- 10.1.6. Analysis by Target Pathway
- 10.1.7. Word Cloud Analysis: Emerging Focus Areas
- 10.1.8. Analysis by Drug and Type of Partnership
- 10.1.9. Analysis by Type of Partner
- 10.1.10. Analysis by Popular Disease Indication
- 10.1.11. Analysis by Popular Disease Indication and Type of Partnership
- 10.1.12. Analysis by Therapeutic Area
- 10.1.13. Analysis by Therapeutic Area and Type of Partnership
- 10.1.14. Regional Analysis of Partnerships
- 10.1.15. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS

11.1. Next Generation Complement Therapeutics: List of Funding and Investments
- 11.1.1. Cumulative Year-wise Trend
- 11.1.2. Analysis by Amount Invested per Year
- 11.1.3. Analysis by Type of Funding and Year of Establishment
- 11.1.4. Analysis of Instances by Type of Funding
- 11.1.5. Analysis of Amount Invested by Type of Funding
- 11.1.6. Analysis by Year, Type of Funding and Amount Invested
- 11.1.7. Most Active Investors: Analysis by Number of Instances
- 11.1.8. Most Active Players: Analysis by Number of Funding Instances
- 11.1.9. Most Active Players: Analysis by Amount Raised
- 11.1.10. Analysis of Amount by Drug
- 11.1.11. Analysis of Number of Instances by Drug
- 11.1.12. Summary of Investments

12. BIG PHARMA PLAYERS

12.1. Analysis Methodology and Key Parameters
12.2. Scoring of Parameters
12.3. Big Pharma Players: Information on Revenues Generated
- 12.3.1. Analysis by Supplier Strength
- 12.3.2. Analysis by Portfolio Strength
- 12.3.3. Analysis by Portfolio Diversity
- 12.3.4. Benchmarking: Spider Web Analysis
- 12.3.5. Benchmarking: Harvey Ball Analysis
- 12.3.6. Benchmarking: Wind Rose Chart

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

13.1. Forecast Methodology and Key Parameters
13.2. Global Next Generation Complement Therapeutics Market, Till 2035
13.3. Global Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035
- 13.3.1. Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035: Distribution by Target Disease Indication
  - 13.3.1.1. Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, Till 2035
  - 13.3.1.2. Next Generation Complement Therapeutics Market for Hereditary Angioedema, Till 2035
- 13.3.2. Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035: Distribution by Type of Molecule
  - 13.3.2.1. Next Generation Complement Therapeutics Market for Biologics, Till 2035
  - 13.3.2.2. Next Generation Complement Therapeutics Market for Small Molecules, Till 2035
- 13.3.3. Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035: Distribution by Target Pathway
  - 13.3.3.1. Next Generation Complement Therapeutics Market for Terminal Pathway, Till 2035
  - 13.3.3.2. Next Generation Complement Therapeutics Market for Classical Pathway, Till 2035
  - 13.3.3.3. Next Generation Complement Therapeutics Market for Alternate Pathway, Till 2035
  - 13.3.3.4. Next Generation Complement Therapeutics Market for Lectin Pathway, Till 2035
- 13.3.4. Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035: Distribution by Type of Therapy
  - 13.3.4.1. Next Generation Complement Therapeutics Market for Monotherapy, Till 2035
  - 13.3.4.2. Next Generation Complement Therapeutics Market for Combination Therapy, Till 2035
- 13.3.5. Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035: Distribution by Route of Administration
  - 13.3.5.1. Next Generation Complement Therapeutics Market for Intravenous Drugs, Till 2035
  - 13.3.5.2. Next Generation Complement Therapeutics Market for Subcutaneous Drugs, Till 2035
  - 13.3.5.3. Next Generation Complement Therapeutics Market for Oral Drugs, Till 2035
13.4. Product-wise Sales Forecast for Marketed Drugs
- 13.4.1. Berinert (CSL Behring)
  - 13.4.1.1. Sales Forecast (USD Billion)
- 13.4.2. EMPAVELI (Apellis Pharmaceuticals)
  - 13.4.2.1. Sales Forecast (USD Billion)
- 13.4.3. ORLADEYO (BioCryst Pharmaceuticals)
  - 13.4.3.1. Sales Forecast (USD Billion)
- 13.4.4. Ruconest (Pharming)
  - 13.4.4.1. Sales Forecast (USD Billion)
- 13.4.5. Soliris (Alexion Pharmaceuticals)
  - 13.4.5.1. Sales Forecast (USD Billion)
- 13.4.6. Takhzyro (Takeda)
  - 13.4.6.1. Sales Forecast (USD Billion)
- 13.4.7. Ultomiris (Alexion Pharmaceuticals)
  - 13.4.7.1. Sales Forecast (USD Billion)
13.5. Global Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035
- 13.5.1. Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035: Distribution by Target Disease Indication
  - 13.5.1.1. Next Generation Complement Therapeutics Market for Atypical Hemolytic Uremic Syndrome, Till 2035
  - 13.5.1.2. Next Generation Complement Therapeutics Market for Cardiac Transplantation Rejection, Till 2035
  - 13.5.1.3. Next Generation Complement Therapeutics Market for Cold Agglutinin Disease, Till 2035
  - 13.5.1.4. Next Generation Complement Therapeutics Market for COVID-19, Till 2035
  - 13.5.1.5. Next Generation Complement Therapeutics Market for Guillain-Barre Syndrome, Till 2035
  - 13.5.1.6. Next Generation Complement Therapeutics Market for Generalized Myasthenia Gravis, Till 2035
  - 13.5.1.7. Next Generation Complement Therapeutics Market for Neuromyelitis Optica, Till 2035
  - 13.5.1.8. Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, Till 2035
- 13.5.2. Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035: Distribution by Therapeutic Area
  - 13.5.2.1. Next Generation Complement Therapeutics Market for Cardiovascular Disorders, Till 2035
  - 13.5.2.2. Next Generation Complement Therapeutics Market for Hematological and Vascular Disorders, Till 2035
  - 13.5.2.3. Next Generation Complement Therapeutics Market for Infectious Diseases, Till 2035
  - 13.5.2.4. Next Generation Complement Therapeutics Market for Neurological Disorders, Till 2035
  - 13.5.2.5. Next Generation Complement Therapeutics Market for Neuromuscular Disorders, Till 2035
  - 13.5.2.6. Next Generation Complement Therapeutics Market for Genetic Disorders, Till 2035
- 13.5.3. Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035: Distribution by Target Pathway
  - 13.5.3.1. Next Generation Complement Therapeutics Market for Terminal Pathway, Till 2035
  - 13.5.3.2. Next Generation Complement Therapeutics Market for Lectin Pathway, Till 2035
  - 13.5.3.3. Next Generation Complement Therapeutics Market for Classical Pathway, Till 2035
- 13.5.4. Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035: Distribution by Type of Therapy
  - 13.5.4.1. Next Generation Complement Therapeutics Market for Monotherapy, Till 2035
  - 13.5.4.2. Next Generation Complement Therapeutics Market for Combination Therapy, Till 2035
- 13.5.5. Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035: Distribution by Route of Administration
  - 13.5.5.1. Next Generation Complement Therapeutics Market for Intravenous Drugs, Till 2035
  - 13.5.5.2. Next Generation Complement Therapeutics Market for Subcutaneous Drugs, Till 2035
- 13.5.6. Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035: Distribution by Geography
  - 13.5.6.1. Next Generation Complement Therapeutics Market in North America, Till 2035
    - 13.5.6.1.1. Next Generation Complement Therapeutics Market in US, Till 2035
    - 13.5.6.1.2. Next Generation Complement Therapeutics Market in Canada, Till 2035
  - 13.5.6.2. Next Generation Complement Therapeutics Market in Europe, Till 2035
    - 13.5.6.2.1. Next Generation Complement Therapeutics Market in UK, Till 2035
    - 13.5.6.2.2. Next Generation Complement Therapeutics Market in Germany, Till 2035
    - 13.5.6.2.3. Next Generation Complement Therapeutics Market in France, Till 2035
    - 13.5.6.2.4. Next Generation Complement Therapeutics Market in Italy, Till 2035
    - 13.5.6.2.5. Next Generation Complement Therapeutics Market in Spain, Till 2035
  - 13.5.6.3. Next Generation Complement Therapeutics Market in Asia Pacific, Till 2035
    - 13.5.6.3.1. Next Generation Complement Therapeutics Market in Australia, Till 2035
    - 13.5.6.3.2. Next Generation Complement Therapeutics Market in Japan, Till 2035
    - 13.5.6.3.3. Next Generation Complement Therapeutics Market in China, Till 2035
    - 13.5.6.3.4. Next Generation Complement Therapeutics Market in India, Till 2035
13.6. Product-wise Sales Forecast for Phase III Drugs
- 13.6.1. Narsoplimab (Omeros)
  - 13.6.1.1. Target Patient Population
  - 13.6.1.2. Sales Forecast (USD Billion)
  - 13.6.1.3. Net Present Value (USD Billion)
  - 13.6.1.4. Value Creation Analysis
- 13.6.2. REGN3918 (Regeneron)
  - 13.6.2.1. Target Patient Population
  - 13.6.2.2. Sales Forecast (USD Billion)
  - 13.6.2.3. Net Present Value (USD Billion)
  - 13.6.2.4. Value Creation Analysis
- 13.6.3. RG6107 (Ruconest)
  - 13.6.3.1. Target Patient Population
  - 13.6.3.2. Sales Forecast (USD Billion)
  - 13.6.3.3. Net Present Value (USD Billion)
  - 13.6.3.4. Value Creation Analysis
- 13.6.4. rVA576 (Akari Therapeutics)
  - 13.6.4.1. Target Patient Population
  - 13.6.4.2. Sales Forecast (USD Billion)
  - 13.6.4.3. Net Present Value (USD Billion)
  - 13.6.4.4. Value Creation Analysis
- 13.6.5. SAR445088 (Sanofi)
  - 13.6.5.1. Target Patient Population
  - 13.6.5.2. Sales Forecast (USD Billion)
  - 13.6.5.3. Net Present Value (USD Billion)
  - 13.6.5.4. Value Creation Analysis
- 13.6.6. Soliris (Alexion Pharmaceuticals)
  - 13.6.6.1. Target Patient Population
  - 13.6.6.2. Sales Forecast (USD Billion)
  - 13.6.6.3. Net Present Value (USD Billion)
  - 13.6.6.4. Value Creation Analysis
- 13.6.7. Sutimlimab (Bioverativ)
  - 13.6.7.1. Target Patient Population
  - 13.6.7.2. Sales Forecast (USD Billion)
  - 13.6.7.3. Net Present Value (USD Billion)
  - 13.6.7.4. Value Creation Analysis
- 13.6.8. Vilobelimab (InflaRx)
  - 13.6.8.1. Target Patient Population
  - 13.6.8.2. Sales Forecast (USD Billion)
  - 13.6.8.3. Net Present Value (USD Billion)
  - 13.6.8.4. Value Creation Analysis
- 13.6.9. Zilucoplan (UCB)
  - 13.6.9.1. Target Patient Population
  - 13.6.9.2. Sales Forecast (USD Billion)
  - 13.6.9.3. Net Present Value (USD Billion)
  - 13.6.9.4. Value Creation Analysis
13.7. Summary: Phase III Drugs

14. EXPERT OPINION

14.1. Company A
- 14.1.1. Overview of Organization
- 14.1.2. Expert Opinion: Physician
14.2. Company B
- 14.2.1. Overview of Organization
- 14.2.2. Expert Opinion: Hematologist Oncologist
14.3. Company C
- 14.3.1. Overview of Organization
- 14.3.2. Expert Opinion: Senior Scientific Consultant
14.4. Company D
- 14.4.1. Overview of Organization
- 14.4.2. Expert Opinion: Nephrology Clinician-Scientist
14.5. Company E
- 14.5.1. Overview of Organization
- 14.5.2. Expert Opinion: Professor of Nephrology

15. APPENDIX 1: LIST OF FIGURES AND TABLES

16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

简介目录图表

List of Tables

Table 3.1 Sources of Key Complement Proteins
Table 3.2 Functions of Complement Proteins of Classical Pathway
Table 3.3 Diseases Related to Defects in Complement Proteins
Table 4.1 Next Generation Complement Therapeutics: Development Pipeline
Table 4.2 List of Drugs with Special Designations
Table 4.3 Next Generation Complement Therapeutics: List of Developers
Table 5.1 Amgen: Product Portfolio
Table 5.2 Recent Developments and Future Outlook
Table 5.3 CSL Behring: Product Portfolio
Table 5.4 Recent Developments and Future Outlook
Table 5.5 Innovent Biologics: Product Portfolio
Table 5.6 Recent Developments and Future Outlook
Table 5.7 Novartis: Product Portfolio
Table 5.8 Recent Developments and Future Outlook
Table 5.9 Regeneron: Product Portfolio
Table 5.10 Recent Developments and Future Outlook
Table 5.11 Roche: Product Portfolio
Table 5.12 Recent Developments and Future Outlook
Table 5.13 Sanofi: Product Portfolio
Table 5.14 Recent Developments and Future Outlook
Table 5.15 Takeda: Product Portfolio
Table 5.16 Recent Developments and Future Outlook
Table 5.17 UCB: Product Portfolio
Table 5.18 Recent Developments and Future Outlook
Table 6.1 Next Generation Complement Therapeutics: List of Clinical Trials
Table 7.1 Next Generation Complement Therapeutics: List of Publications
Table 9.1 Next Generation Complement Therapeutics: List of Patents
Table 10.1 Next Generation Complement Therapeutics: List of Partnerships and Collaborations, Since 2014
Table 11.1 Next Generation Complement Therapeutics: List of Funding and Investments
Table 12.1 Big Pharma Players: Information on Revenues Generated
Table 13.1 Next Generation Complement Therapeutics: List of Forecasted Marketed Drugs
Table 13.2 Next Generation Complement Therapeutics: List of Forecasted Phase III Drugs
Table 13.3 Summary: Phase III Drugs
Table 15.1 Global Next Generation Complement Therapeutics Market, Till 2035 (USD Billion)
Table 15.2 Global Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion)
Table 15.3 Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion): Distribution by Target Disease Indication
Table 15.4 Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, Till 2035 (USD Billion)
Table 15.5 Next Generation Complement Therapeutics Market for Hereditary Angioedema, Till 2035 (USD Billion)
Table 15.6 Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion): Distribution by Type of Molecule
Table 15.7 Next Generation Complement Therapeutics Market for Biologics, Till 2035 (USD Billion)
Table 15.8 Next Generation Complement Therapeutics Market for Small Molecules, Till 2035 (USD Billion)
Table 15.9 Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion): Distribution by Target Pathway
Table 15.10 Next Generation Complement Therapeutics Market for Terminal Pathway, Till 2035 (USD Billion)
Table 15.11 Next Generation Complement Therapeutics Market for Classical Pathway, Till 2035 (USD Billion)
Table 15.12 Next Generation Complement Therapeutics Market for Alternate Pathway, Till 2035 (USD Billion)
Table 15.15 Next Generation Complement Therapeutics Market for Lectin Pathway, Till 2035 (USD Billion)
Table 15.14 Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion): Distribution by Type of Therapy
Table 15.15 Next Generation Complement Therapeutics Market for Monotherapy, Till 2035 (USD Billion)
Table 15.16 Next Generation Complement Therapeutics Market for Combination Therapy, Till 2035 (USD Billion)
Table 15.17 Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion): Distribution by Route of Administration
Table 15.18 Next Generation Complement Therapeutics Market for Intravenous Drugs, Till 2035 (USD Billion)
Table 15.19 Next Generation Complement Therapeutics Market for Subcutaneous Drugs, Till 2035 (USD Billion)
Table 15.20 Next Generation Complement Therapeutics Market for Oral Drugs, Till 2035 (USD Billion)
Table 15.21 Berinert Sales Forecast, Till 2035 (USD Billion)
Table 15.22 EMPAVELI Sales Forecast, Till 2035 (USD Billion)
Table 15.23 ORLADEYO Sales Forecast, Till 2035 (USD Billion)
Table 15.24 Ruconest Sales Forecast, Till 2035 (USD Billion)
Table 15.25 Soliris Sales Forecast, Till 2035 (USD Billion)
Table 15.26 Takhzyro Sales Forecast, Till 2035 (USD Billion)
Table 15.27 Ultomiris Sales Forecast, Till 2035 (USD Billion)
Table 15.28 Global Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion)
Table 15.29 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Target Disease Indication
Table 15.30 Next Generation Complement Therapeutics Market for Atypical Hemolytic Uremic Syndrome, Till 2035 (USD Billion)
Table 15.31 Next Generation Complement Therapeutics Market for Cardiac Transplantation Rejection, Till 2035 (USD Billion)
Table 15.32 Next Generation Complement Therapeutics Market for Cold Agglutinin Disease, Till 2035 (USD Billion)
Table 15.33 Next Generation Complement Therapeutics Market for COVID-19, Till 2035 (USD Billion)
Table 15.34 Next Generation Complement Therapeutics Market for Guillain-Barre Syndrome, Till 2035 (USD Billion)
Table 15.35 Next Generation Complement Therapeutics Market for Generalized Myasthenia Gravis, Till 2035 (USD Billion)
Table 15.36 Next Generation Complement Therapeutics Market for Neuromyelitis Optica, Till 2035 (USD Billion)
Table 15.37 Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, Till 2035 (USD Billion)
Table 15.38 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Therapeutic Area
Table 15.39 Next Generation Complement Therapeutics Market for Cardiovascular Disorders, Till 2035 (USD Billion)
Table 15.40 Next Generation Complement Therapeutics Market for Hematological and Vascular Disorders, Till 2035 (USD Billion)
Table 15.41 Next Generation Complement Therapeutics Market for Infectious Diseases, Till 2035 (USD Billion)
Table 15.42 Next Generation Complement Therapeutics Market for Neurological Disorders, Till 2035 (USD Billion)
Table 15.43 Next Generation Complement Therapeutics Market for Neuromuscular Disorders, Till 2035 (USD Billion)
Table 15.44 Next Generation Complement Therapeutics Market for Genetic Disorders, Till 2035 (USD Billion)
Table 15.45 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Target Pathway
Table 15.46 Next Generation Complement Therapeutics Market for Terminal Pathway, Till 2035 (USD Billion)
Table 15.47 Next Generation Complement Therapeutics Market for Lectin Pathway, Till 2035 (USD Billion)
Table 15.48 Next Generation Complement Therapeutics Market for Classical Pathway, Till 2035 (USD Billion)
Table 15.49 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Type of Therapy
Table 15.50 Next Generation Complement Therapeutics Market for Monotherapy, Till 2035 (USD Billion)
Table 15.51 Next Generation Complement Therapeutics Market for Combination Therapy, Till 2035 (USD Billion)
Table 15.52 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Route of Administration
Table 15.53 Next Generation Complement Therapeutics Market for Intravenous Drugs, Till 2035 (USD Billion)
Table 15.54 Next Generation Complement Therapeutics Market for Subcutaneous Drugs, Till 2035 (USD Billion)
Table 15.55 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Geography
Table 15.56 Next Generation Complement Therapeutics Market in North America, Till 2035 (USD Billion)
Table 15.57 Next Generation Complement Therapeutics Market in US, Till 2035 (USD Billion)
Table 15.58 Next Generation Complement Therapeutics Market in Canada, Till 2035 (USD Billion)
Table 15.59 Next Generation Complement Therapeutics Market in Europe, Till 2035 (USD Billion)
Table 15.60 Next Generation Complement Therapeutics Market in UK, Till 2035 (USD Billion)
Table 15.61 Next Generation Complement Therapeutics Market in Germany, Till 2035 (USD Billion)
Table 15.62 Next Generation Complement Therapeutics Market in France, Till 2035 (USD Billion)
Table 15.63 Next Generation Complement Therapeutics Market in Italy, Till 2035 (USD Billion)
Table 15.64 Next Generation Complement Therapeutics Market in Spain, Till 2035 (USD Billion)
Table 15.65 Next Generation Complement Therapeutics Market in Asia Pacific, Till 2035 (USD Billion)
Table 15.66 Next Generation Complement Therapeutics Market in Australia, Till 2035 (USD Billion)
Table 15.67 Next Generation Complement Therapeutics Market in Japan, Till 2035 (USD Billion)
Table 15.68 Next Generation Complement Therapeutics Market in China, Till 2035 (USD Billion)
Table 15.69 Next Generation Complement Therapeutics Market in India, Till 2035 (USD Billion)
Table 15.70 Narsoplimab: Target Patient Population
Table 15.71 Narsoplimab Sales Forecast, Till 2035 (USD Billion)
Table 15.72 REGN3918: Target Patient Population
Table 15.73 REGN3918 Sales Forecast, Till 2035 (USD Billion)
Table 15.74 RG6107: Target Patient Population
Table 15.75 RG6107 Sales Forecast, Till 2035 (USD Billion)
Table 15.76 rVA576: Target Patient Population
Table 15.77 rVA576 Sales Forecast, Till 2035 (USD Billion)
Table 15.78 SAR445088: Target Patient Population
Table 15.79 SAR445088 Sales Forecast, Till 2035 (USD Billion)
Table 15.80 Soliris: Target Patient Population
Table 15.81 Soliris Sales Forecast, Till 2035 (USD Billion)
Table 15.82 Sutimlimab: Target Patient Population
Table 15.83 Sutimlimab Sales Forecast, Till 2035 (USD Billion)
Table 15.84 Vilobelimab: Target Patient Population
Table 15.85 Vilobelimab Sales Forecast, Till 2035 (USD Billion)
Table 15.86 Zilucoplan: Target Patient Population
Table 15.87 Zilucoplan Sales Forecast, Till 2035 (USD Billion)

List of Figures

Figure 3.1 Immune Cells Involved in Complement System
Figure 3.2 Role of Complement in Homeostasis and Stress Conditions
Figure 3.3 Activation of Complement System
Figure 3.4 Steps in Complement Activation
Figure 3.5 Pathways of Complement System
Figure 3.6 Consequences of a Dysregulated Complement System
Figure 3.7 Types of Complement Therapeutics
Figure 3.8 Limitations of Complement Therapeutics
Figure 3.9 Future of Next Generation Complement Therapeutics
Figure 4.1 Next Generation Complement Therapeutics: Distribution by Status of Development
Figure 4.2 Next Generation Complement Therapeutics: Distribution by Type of Molecule
Figure 4.3 Next Generation Complement Therapeutics: Distribution by Status of Development and Type of Molecule
Figure 4.4 Next Generation Complement Therapeutics: Distribution by Type of Drug
Figure 4.5 Next Generation Complement Therapeutics: Distribution by Biological Target
Figure 4.6 Next Generation Complement Therapeutics: Distribution by Target Pathway
Figure 4.7 Next Generation Complement Therapeutics: Distribution by Mechanism of Action
Figure 4.8 Next Generation Complement Therapeutics: Distribution by Mechanism of Action and Target Pathway
Figure 4.9 Next Generation Complement Therapeutics: Distribution by Target Disease Indication(s)
Figure 4.10 Next Generation Complement Therapeutics: Distribution by Status of Development and Target Disease Indication(s)
Figure 4.11 Next Generation Complement Therapeutics: Distribution by Therapeutic Area
Figure 4.12 Next Generation Complement Therapeutics: Distribution by Therapeutic Area and Type of Molecule
Figure 4.13 Next Generation Complement Therapeutics: Distribution by Route of Administration
Figure 4.14 Next Generation Complement Therapeutics: Distribution by Type of Therapy
Figure 4.15 Next Generation Complement Therapeutics: Distribution by Dosing Frequency
Figure 4.16 Grid Analysis: Distribution by Type of Therapy, Type of Molecule, Route of Administration and Mechanism of Action
Figure 4.17 Next Generation Complement Therapeutics: Distribution by Special Designation
Figure 4.18 Next Generation Complement Therapeutics Developers: Distribution by Year of Establishment
Figure 4.19 Next Generation Complement Therapeutics Developers: Distribution by Company Size
Figure 4.20 Next Generation Complement Therapeutics Developers: Distribution by Region of Headquarters
Figure 4.21 Next Generation Complement Therapeutics Developers: Distribution by Company Size and Region of Headquarters
Figure 4.22 Leading Players: Distribution by Number of Therapeutics
Figure 5.1 Amgen: Financial Information
Figure 5.2 CSL Behring: Financial Information
Figure 5.3 Innovent Biologics: Financial Information
Figure 5.4 Novartis: Financial Information
Figure 5.5 Regeneron: Financial Information
Figure 5.6 Roche: Financial Information
Figure 5.7 Sanofi: Financial Information
Figure 5.8 Takeda: Financial Information
Figure 5.9 UCB: Financial Information
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since Pre-2016
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Status, Since Pre-2001
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 6.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 6.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.8 Clinical Trial Analysis: Distribution by Type of Study
Figure 6.9 Clinical Trial Analysis: Distribution by Study Design
Figure 6.10 Most Active Industry Players: Distribution by Number of Trials
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 6.12 Clinical Trial Analysis: Distribution by Disease Indication
Figure 6.13 Most Popular Therapeutic Areas: Distribution by Number of Trials
Figure 6.14 Clinical Trial Analysis: Distribution by Type of Treatment
Figure 6.15 Clinical Trial Analysis: Distribution by Type of Drug
Figure 6.16 Word Cloud Analysis: Emerging Focus Areas
Figure 6.17 Clinical Trial Analysis: Distribution by Top Indications and Phase of the Trial
Figure 6.18 Clinical Trial Analysis: Distribution by Top Indications and Leading Industry Players
Figure 6.19 Clinical Trial Analysis: Distribution by Trial Location
Figure 6.20 Clinical Trial Analysis: Distribution by Geography and Trial Status
Figure 7.1 Publication Analysis: Distribution by Year of Publication
Figure 7.2 Word Cloud Analysis: Emerging Focus Areas
Figure 7.3 Top Authors: Distribution by Number of Publications
Figure 7.4 Key Journals: Distribution by Number of Publications
Figure 7.5 Key Journals: Distribution by Impact Factor
Figure 7.6 Popular Indications: Distribution by Number of Publications
Figure 7.7 Popular Therapeutic Areas: Distribution by Number of Publications
Figure 8.1 Grant Analysis: Distribution by Year of Grants Awarded
Figure 8.2 Grant Analysis: Distribution by Amount Awarded
Figure 8.3 Grant Analysis: Distribution by Funding Institute Center
Figure 8.4 Grant Analysis: Distribution by Support Period
Figure 8.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 8.6 Grant Analysis: Distribution by Type of Grant
Figure 8.7 Grant Analysis: Distribution by Activity Code
Figure 8.8 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.9 Popular Recipient Organizations: Distribution by Amount Awarded
Figure 8.10 Popular NIH Departments: Distribution by Number of Grants
Figure 8.11 Grant Analysis: Distribution by Study Section
Figure 8.12 Grant Analysis: Distribution by Type of Recipient Organization
Figure 8.13 Word Cloud Analysis: Emerging Focus Areas
Figure 8.14 Grants Analysis: Distribution by Purpose of Grant
Figure 8.15 Prominent Program Officers: Distribution by Number of Grants
Figure 8.16 Grant Analysis: Distribution by Location of Recipient Organizations
Figure 9.1 Patent Analysis: Distribution by Patent Publication Year
Figure 9.2 Patent Analysis: Year-wise Distribution of Granted Patents
Figure 9.3 Patent Analysis: Distribution by Type of Patent
Figure 9.4 Patent Analysis: Distribution by Granted Patents and Patent Applications
Figure 9.5 Patent Analysis: Distribution by Geography
Figure 9.6 Patent Analysis: Distribution by CPC Symbols
Figure 9.7 Patent Analysis: Distribution by Type of Applicant
Figure 9.8 Patent Analysis: Distribution of Patents by Age
Figure 9.9 Word Cloud Analysis: Emerging Focus Areas
Figure 9.10 Leading Industry Players: Distribution by Number of Patents
Figure 9.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 9.12 Leading Individual Assignees: Distribution by Number of Patents
Figure 9.13 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 9.14 Patent Valuation: Distribution by Relative Valuation
Figure 10.1 Partnerships and Collaborations: Distribution by Year-wise Trend of Partnership
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Most Popular Drug: Distribution by Number of Partnerships
Figure 10.5 Partnerships and Collaborations: Distribution by Biological Target
Figure 10.6 Partnerships and Collaborations: Distribution by Target Pathway
Figure 10.7 Word Cloud Analysis: Emerging Focus Areas
Figure 10.8 Partnerships and Collaborations: Distribution by Drug and Type of Partnership
Figure 10.9 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.10 Partnerships and Collaborations: Distribution by Popular Disease Indication
Figure 10.11 Partnerships and Collaborations: Distribution by Popular Disease Indication and Type of Partnership
Figure 10.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.13 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Figure 10.14 Regional Distribution of Partnerships
Figure 10.15 Intercontinental and Intracontinental Agreements
Figure 11.1 Funding and Investments: Cumulative Year-wise Trend
Figure 11.2 Funding and Investments: Distribution by Amount Invested per Year
Figure 11.3 Funding and Investments: Distribution by Type of Funding and Year of Establishment
Figure 11.4 Funding and Investments: Distribution of Instances by Type of Funding
Figure 11.5 Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 11.6 Funding and Investments: Distribution by Year, Type of Funding and Amount Invested
Figure 11.7 Most Active Investors: Distribution by Number of Instances
Figure 11.8 Most Active Players: Distribution by Number of Funding Instances
Figure 11.9 Most Active Players: Distribution by Amount Raised
Figure 11.10 Funding and Investments: Distribution of Amount by Drug
Figure 11.11 Funding and Investments: Distribution of Number of Instances by Drug
Figure 11.12 Funding and Investments: Summary of Investments
Figure 12.1 Distribution by Supplier Strength
Figure 12.2 Distribution by Portfolio Strength
Figure 12.3 Distribution by Portfolio Diversity
Figure 12.4 Benchmarking: Spider Web Analysis
Figure 12.5 Benchmarking: Harvey Ball Analysis
Figure 12.6 Benchmarking: Wind Rose Chart
Figure 13.1 Global Next Generation Complement Therapeutics Market, Till 2035 (USD Billion)
Figure 13.2 Global Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion)
Figure 13.3 Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion): Distribution by Target Disease Indication
Figure 13.4 Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, Till 2035 (USD Billion)
Figure 13.5 Next Generation Complement Therapeutics Market for Hereditary Angioedema, Till 2035 (USD Billion)
Figure 13.6 Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion): Distribution by Type of Molecule
Figure 13.7 Next Generation Complement Therapeutics Market for Biologics, Till 2035 (USD Billion)
Figure 13.8 Next Generation Complement Therapeutics Market for Small Molecules, Till 2035 (USD Billion)
Figure 13.9 Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion): Distribution by Target Pathway
Figure 13.10 Next Generation Complement Therapeutics Market for Terminal Pathway, Till 2035 (USD Billion)
Figure 13.11 Next Generation Complement Therapeutics Market for Classical Pathway, Till 2035 (USD Billion)
Figure 13.12 Next Generation Complement Therapeutics Market for Alternate Pathway, Till 2035 (USD Billion)
Figure 13.13 Next Generation Complement Therapeutics Market for Lectin Pathway, Till 2035 (USD Billion)
Figure 13.14 Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion): Distribution by Type of Therapy
Figure 13.15 Next Generation Complement Therapeutics Market for Monotherapy, Till 2035 (USD Billion)
Figure 13.16 Next Generation Complement Therapeutics Market for Combination Therapy, Till 2035 (USD Billion)
Figure 13.17 Next Generation Complement Therapeutics Market for Marketed Drugs, Till 2035 (USD Billion): Distribution by Route of Administration
Figure 13.18 Next Generation Complement Therapeutics Market for Intravenous Drugs, Till 2035 (USD Billion)
Figure 13.19 Next Generation Complement Therapeutics Market for Subcutaneous Drugs, Till 2035 (USD Billion)
Figure 13.20 Next Generation Complement Therapeutics Market for Oral Drugs, Till 2035 (USD Billion)
Figure 13.21 Berinert Sales Forecast, Till 2035 (USD Billion)
Figure 13.22 EMPAVELI Sales Forecast, Till 2035 (USD Billion)
Figure 13.23 ORLADEYO Sales Forecast, Till 2035 (USD Billion)
Figure 13.24 Ruconest Sales Forecast, Till 2035 (USD Billion)
Figure 13.25 Soliris Sales Forecast, Till 2035 (USD Billion)
Figure 13.26 Takhzyro Sales Forecast, Till 2035 (USD Billion)
Figure 13.27 Ultomiris Sales Forecast, Till 2035 (USD Billion)
Figure 13.28 Global Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion)
Figure 13.29 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Target Disease Indication
Figure 13.30 Next Generation Complement Therapeutics Market for Atypical Hemolytic Uremic Syndrome, Till 2035 (USD Billion)
Figure 13.31 Next Generation Complement Therapeutics Market for Cardiac Transplantation Rejection, Till 2035 (USD Billion)
Figure 13.32 Next Generation Complement Therapeutics Market for Cold Agglutinin Disease, Till 2035 (USD Billion)
Figure 13.33 Next Generation Complement Therapeutics Market for COVID-19, Till 2035 (USD Billion)
Figure 13.34 Next Generation Complement Therapeutics Market for Guillain-Barre Syndrome, Till 2035 (USD Billion)
Figure 13.35 Next Generation Complement Therapeutics Market for Generalized Myasthenia Gravis, Till 2035 (USD Billion)
Figure 13.36 Next Generation Complement Therapeutics Market for Neuromyelitis Optica, Till 2035 (USD Billion)
Figure 13.37 Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, Till 2035 (USD Billion)
Figure 13.38 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Therapeutic Area
Figure 13.39 Next Generation Complement Therapeutics Market for Cardiovascular Disorders, Till 2035 (USD Billion)
Figure 13.40 Next Generation Complement Therapeutics Market for Hematological and Vascular Disorders, Till 2035 (USD Billion)
Figure 13.41 Next Generation Complement Therapeutics Market for Infectious Diseases, Till 2035 (USD Billion)
Figure 13.42 Next Generation Complement Therapeutics Market for Neurological Disorders, Till 2035 (USD Billion)
Figure 13.43 Next Generation Complement Therapeutics Market for Neuromuscular Disorders, Till 2035 (USD Billion)
Figure 13.44 Next Generation Complement Therapeutics Market for Genetic Disorders, Till 2035 (USD Billion)
Figure 13.45 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Target Pathway
Figure 13.46 Next Generation Complement Therapeutics Market for Terminal Pathway, Till 2035 (USD Billion)
Figure 13.47 Next Generation Complement Therapeutics Market for Lectin Pathway, Till 2035 (USD Billion)
Figure 13.48 Next Generation Complement Therapeutics Market for Classical Pathway, Till 2035 (USD Billion)
Figure 13.49 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Type of Therapy
Figure 13.50 Next Generation Complement Therapeutics Market for Monotherapy, Till 2035 (USD Billion)
Figure 13.51 Next Generation Complement Therapeutics Market for Combination Therapy, Till 2035 (USD Billion)
Figure 13.52 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Route of Administration
Figure 13.53 Next Generation Complement Therapeutics Market for Intravenous Drugs, Till 2035 (USD Billion)
Figure 13.54 Next Generation Complement Therapeutics Market for Subcutaneous Drugs, Till 2035 (USD Billion)
Figure 13.55 Next Generation Complement Therapeutics Market for Phase III Drugs, Till 2035 (USD Billion): Distribution by Geography
Figure 13.56 Next Generation Complement Therapeutics Market in North America, Till 2035 (USD Billion)
Figure 13.57 Next Generation Complement Therapeutics Market in US, Till 2035 (USD Billion)
Figure 13.58 Next Generation Complement Therapeutics Market in Canada, Till 2035 (USD Billion)
Figure 13.59 Next Generation Complement Therapeutics Market in Europe, Till 2035 (USD Billion)
Figure 13.60 Next Generation Complement Therapeutics Market in UK, Till 2035 (USD Billion)
Figure 13.61 Next Generation Complement Therapeutics Market in Germany, Till 2035 (USD Billion)
Figure 13.62 Next Generation Complement Therapeutics Market in France, Till 2035 (USD Billion)
Figure 13.63 Next Generation Complement Therapeutics Market in Italy, Till 2035 (USD Billion)
Figure 13.64 Next Generation Complement Therapeutics Market in Spain, Till 2035 (USD Billion)
Figure 13.65 Next Generation Complement Therapeutics Market in Asia Pacific, Till 2035 (USD Billion)
Figure 13.66 Next Generation Complement Therapeutics Market in Australia, Till 2035 (USD Billion)
Figure 13.67 Next Generation Complement Therapeutics Market in Japan, Till 2035 (USD Billion)
Figure 13.68 Next Generation Complement Therapeutics Market in China, Till 2035 (USD Billion)
Figure 13.69 Next Generation Complement Therapeutics Market in India, Till 2035 (USD Billion)
Figure 13.70 Narsoplimab: Target Patient Population
Figure 13.71 Narsoplimab Sales Forecast, Till 2035 (USD Billion)
Figure 13.72 REGN3918: Target Patient Population
Figure 13.73 REGN3918 Sales Forecast, Till 2035 (USD Billion)
Figure 13.74 RG6107: Target Patient Population
Figure 13.75 RG6107 Sales Forecast, Till 2035 (USD Billion)
Figure 13.76 rVA576: Target Patient Population
Figure 13.77 rVA576 Sales Forecast, Till 2035 (USD Billion)
Figure 13.78 SAR445088: Target Patient Population
Figure 13.79 SAR445088 Sales Forecast, Till 2035 (USD Billion)
Figure 13.80 Soliris: Target Patient Population
Figure 13.81 Soliris Sales Forecast, Till 2035 (USD Billion)
Figure 13.82 Sutimlimab: Target Patient Population
Figure 13.83 Sutimlimab Sales Forecast, Till 2035 (USD Billion)
Figure 13.84 Vilobelimab: Target Patient Population
Figure 13.85 Vilobelimab Sales Forecast, Till 2035 (USD Billion)
Figure 13.86 Zilucoplan: Target Patient Population
Figure 13.87 Zilucoplan Sales Forecast, Till 2035 (USD Billion)

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

补体抑制剂市场:产业趋势和全球预测 - 各适应疾病，各治疗领域，各分子类型，各标的途径，治疗类别，各给药途径，主要各地区

Complement Inhibitors Market: Industry Trends and Global Forecasts - Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Key Geographical Regions

全球补体抑制剂市场:成长和趋势

全球补体抑制剂市场：关键洞察

补体抑制剂市场参与企业案例

目录

第1章 序文

第2章 摘要整理

第3章 简介

第4章 下一代补体治疗药:市场形势

第5章 企业简介

第6章 临床试验的分析

第7章 出版物的分析

第8章 津贴分析

第9章 专利分析

第10章 伙伴关係和合作

第11章 与资金筹措投资分析

第12章 大型製药公司

第13章 市场规模的评估与机会分析

第14章 专家的意见

第15章 附录1:图表一览

第16章 附录2:企业·团体一览

GLOBAL COMPLEMENT INHIBITORS MARKET: OVERVIEW

GLOBAL COMPLEMENT INHIBITORS MARKET: GROWTH AND TRENDS

GLOBAL COMPLEMENT INHIBITORS MARKET: KEY INSIGHTS

Example Players in the Complement Inhibitors Market

GLOBAL COMPLEMENT INHIBITORS MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. NEXT GENERATION COMPLEMENT THERAPEUTICS: MARKET LANDSCAPE

5. COMPANY PROFILES

6. CLINICAL TRIAL ANALYSIS

7. PUBLICATION ANALYSIS

8. GRANT ANALYSIS

9. PATENT ANALYSIS

10. PARTNERSHIPS AND COLLABORATIONS

11. FUNDING AND INVESTMENT ANALYSIS

12. BIG PHARMA PLAYERS

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

14. EXPERT OPINION

15. APPENDIX 1: LIST OF FIGURES AND TABLES

16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

List of Figures

第1章序文

第2章摘要整理

第3章简介

第4章下一代补体治疗药:市场形势

第5章企业简介

第6章临床试验的分析

第7章出版物的分析

第8章津贴分析

第9章专利分析

第10章伙伴关係和合作

第11章与资金筹措投资分析

第12章大型製药公司

第13章市场规模的评估与机会分析

第14章专家的意见

第15章附录1:图表一览

第16章附录2:企业·团体一览